ENTITY
Venus MedTech

Venus MedTech (2500 HK)

109
Analysis
Health CareChina
Venus MedTech (HangZhou) Inc. develops and sells cardiovascular devices. The Company offers products including aorta, compression loading and conveying systems, and pulmonary artery. Venus MedTech (HangZhou) markets its products throughout China.
more
Refresh
16 Jan 2020 14:57

2019 Hong Kong IPO Analytics: How Did Insti and Retail Coverage Impact Deal Performance

Since the inception of our IPO research in 2015, the Aequitas Research team has covered over 452 IPOs, which raised over US$100m each, across the...

Logo
512 Views
Share
bullishJiumaojiu
14 Jan 2020 17:44

Jiumaojiu (九毛九) Trading - Off to a Great Start with 638x Oversubscription

Jiumaojiu (9922 HK) raised about US$283m at HK$6.60 per share, the top end of its IPO price range. We have previously covered the IPO...

Share
bullishVenus MedTech
09 Dec 2019 17:08

Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level

Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...

Logo
497 Views
Share
bullishAlphamab Co Ltd
08 Dec 2019 13:19

ECM Weekly (8 Dec 2019) - OneConnect, JS Global, Renrui, Poly Property, Freee, Burger King India

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This...

Share
bullishVenus MedTech
01 Dec 2019 11:18

ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It has...

Share
x